title: Treatment of acute ischemic stroke: recent progress.
abstract: Intravenous thrombolysis with tissue plasminogen activator is currently the most effective treatment of acute ischemic stroke if administerd within 3 hours after symptom onset. Intraarterial thrombolysis by prourokinase is the another choise if the middle cerebral artery is occluded and within less than 6 hours after onset. Although heparin especially a moderate dose is not proved to be effective, a randomized, placebo-controlled trial to determine the safety and efficacy of argatroban (a selective thrombin inhibitor) in patients with acute ischemic stroke was started in USA. Aspirin provides some benefit to patients with acute stroke. However, its effect is not fully satisfactory. Although reports of numerous trials for neuroprotective drugs have been disappointing, edaravone (free radical scavenger) was approved for the treatment of acute ischemic stroke in Japan. In the future, thrombolytic and neuroprotective drugs will be used in combination.
authors.affiliation: Department of Neurology, School of Medicine, Keio University, Tokyo.
authors.forename: Norio
authors.initials: N
authors.lastname: Tanahashi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Fukuuchi
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000379:methods*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D018696:Neuroprotective Agents